Marker Therapeutics

Yahoo Finance • 2 days ago

Exploring Three High Growth Tech Stocks In The US Market

In the last week, the United States market has stayed flat, but over the past 12 months, it has risen by 29%, with earnings expected to grow by 16% per annum in the coming years. In this context of robust growth expectations, identifying h... Full story

Yahoo Finance • 28 days ago

Top 3 High Growth Tech Stocks in the US Market

The United States market has shown robust performance recently, climbing 1.9% in the last week and achieving a remarkable 24% increase over the past year, with earnings projected to grow by 15% annually in the coming years. In such a dynam... Full story

Yahoo Finance • last month

High Growth Tech Stocks To Watch In The US March 2026

The United States market remained flat over the last week but has risen 16% over the past year, with earnings projected to grow by 16% annually in the coming years. In light of these conditions, identifying high growth tech stocks involves... Full story

Yahoo Finance • last month

US High Growth Tech Stocks to Watch Now

Over the last 7 days, the United States market has dropped 2.3%, yet it remains up by 13% over the past year with earnings expected to grow by 16% annually. In this context, identifying high growth tech stocks involves looking for companie... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics GAAP EPS of -$0.12 beats by $0.33, revenue of $1.23M beats by $0.51M

* Marker Therapeutics press release [https://seekingalpha.com/pr/20307922-marker-therapeutics-reports-third-quarter-2025-financial-results-and-provides-business] (MRKR [https://seekingalpha.com/symbol/MRKR]): Q3 GAAP EPS of -$0.12 beats... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patien... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors

HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 6 months ago

Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector... Full story

Yahoo Finance • 7 months ago

Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program

Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other... Full story

Yahoo Finance • 8 months ago

Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 8 months ago

Tuesday's pre-market session: top gainers and losers

Discover the top movers in Tuesday's pre-market session and stay informed about market dynamics. [premarket] GAINERS TICKER CHANGE COMMENT IVVD [https://www.chartmill.com/stock/quote/IVVD/profile] 132.0% Investors witness... Full story

Yahoo Finance • 8 months ago

Marker's lymphoma therapy shows promising response rates in trial

HOUSTON - Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage biotech company with a market capitalization of $16.3 million, reported Tuesday that its Phase 1 APOLLO study of MT-601 therapy demonstrated a 66% objective response rate... Full story

Yahoo Finance • 8 months ago

Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma

Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safe... Full story

Yahoo Finance • 9 months ago

Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference

HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 10 months ago

Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma

HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story

Yahoo Finance • 11 months ago

Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma

Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data reado... Full story

Yahoo Finance • 11 months ago

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignanc... Full story

Yahoo Finance • last year

Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference

HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological maligna... Full story

Yahoo Finance • last year

Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results

Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secu... Full story

Yahoo Finance • last year

Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference

HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignan... Full story